Manufacturer of Controlled Substances; Notice of Registration, 8777 [2011-3405]

Download as PDF 8777 Federal Register / Vol. 76, No. 31 / Tuesday, February 15, 2011 / Notices The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Cerilliant Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Cerilliant Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: February 4, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. factors in 21 U.S.C. 823(a) and determined that the registration of National Center for Natural Products Research-NIDA MProject to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated National Center for Natural Products Research-NIDA MProject to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 4, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–3410 Filed 2–14–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: February 4, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–3405 Filed 2–14–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated October 19, 2010, and published in the Federal Register on October 26, 2010, 75 FR 65659, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Enforcement Administration Drug Manufacturer of Controlled Substances; Notice of Registration [FR Doc. 2011–3407 Filed 2–14–11; 8:45 am] Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated October 8, 2010, and published in the Federal Register on October 20, 2010, (75 FR 64745), National Center for Natural Products Research-NIDA MProject, University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule jdjones on DSK8KYBLC1PROD with NOTICES Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... I I The company plans to cultivate marihuana for the National Institute on Drug Abuse for research approved by the Department of Health and Human Services. No comments or objections have been received. DEA has considered the VerDate Mar<15>2010 15:51 Feb 14, 2011 Jkt 223001 By Notice dated October 8, 2010 and published in the Federal Register on October 20, 2010, 75 FR 64744, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance. The company plans to manufacture a radioactive product used in diagnostic imaging in the diagnosis of Parkinson’s Disease and for manufacture in bulk for investigational new drug (IND) submission and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of GE Healthcare to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated GE Healthcare to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 I I II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted E:\FR\FM\15FEN1.SGM 15FEN1

Agencies

[Federal Register Volume 76, Number 31 (Tuesday, February 15, 2011)]
[Notices]
[Page 8777]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-3405]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated October 8, 2010 and published in the Federal 
Register on October 20, 2010, 75 FR 64744, GE Healthcare, 3350 North 
Ridge Avenue, Arlington Heights, Illinois 60004-1412, made application 
by renewal to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of Cocaine (9041), a basic class of 
controlled substance.
    The company plans to manufacture a radioactive product used in 
diagnostic imaging in the diagnosis of Parkinson's Disease and for 
manufacture in bulk for investigational new drug (IND) submission and 
clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
GE Healthcare to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated GE Healthcare to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with State and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substance listed.

    Dated: February 4, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-3405 Filed 2-14-11; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.